All news

10 November 2026

FDA orders a new eye-risk warning on every GLP-1 weight-loss and diabetes drug

The FDA is making all GLP-1 drugmakers add a label warning about a rare optic nerve condition that can cause sudden vision loss, though it says cause and effect is not proven.

GLP-1 drugs, the class behind Wegovy, Ozempic, Zepbound and Mounjaro, are about to carry one more line of small print. The US Food and Drug Administration said on Monday it will require a new safety warning on every medicine in the class, covering a possible higher risk of a rare eye condition.

What happened

The condition is called NAION, short for nonarteritic anterior ischemic optic neuropathy. In plain English: blood flow to the front of the optic nerve, the cable linking the eye to the brain, drops, and vision can suddenly get worse, sometimes permanently. Doctors still do not fully understand why it happens.

The FDA reviewed clinical trials, real-world patient records and published research. Its analysis of 126 trials covering more than 134,000 patients found about 6.4 NAION cases per 100,000 patient-years (one patient-year is one person taking a drug for a year) among GLP-1 users, versus 3.8 among people on other treatments or a placebo. Several observational studies also pointed to a higher risk, and cases have been reported for every GLP-1 product now on the market.

Two caveats matter. The FDA stresses that NAION is rare, and that it has not established that the drugs cause it. Novo Nordisk, which makes Ozempic and Wegovy, said it still believes the data do not show cause and effect and that it remains confident in its medicines. CNBC said it had asked Eli Lilly, maker of Mounjaro, Zepbound and the pill Foundayo, for comment.

Why it matters

GLP-1s are among the biggest-selling drug classes in the world, and they sit at the center of two very large companies. Eli Lilly is worth about $1.29 trillion on Noorult's latest data, and its revenue over the twelve months to September was roughly $86 billion. Anything that could change how often doctors prescribe these drugs gets watched closely.

Analysts at Citi wrote that the label change will draw attention but should have limited effect on how widely the drugs are used, pointing to the rarity of NAION and the drugs' other benefits. That is their view, not a certainty. It is also not the first warning on these labels: many GLP-1s already carry the FDA's strongest alert, a boxed warning, because the drugs caused thyroid tumors in rodents. Whether that happens in humans is still unknown.

What to watch

  • The updated labels themselves, and how prominently each drugmaker places the new warning.
  • Whether Eli Lilly responds publicly, as Novo Nordisk already has.
  • Any further studies that test whether the link is causal or a coincidence.

The financials for both drugmakers are on Noorult: Eli Lilly and Novo Nordisk.

The companies in this story

Based on reporting by CNBC: FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound. Facts, not advice.

More news